Oxurion NV appoints Tom Graney, CFA as Main Money Officer
Boston-dependent former Vertex and Technology Bio CFO Delivers Significant Operational, US Money Marketplaces and Investor Relations Experience
Leuven, Belgium and Boston, MA, Usa 13th October 2020 – 5.45 p.m. CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical organization acquiring future era normal-of-care therapies for Diabetic Macular Edema (DME), is pleased to announce the appointment of Tom Graney as its Main Economical Officer (CFO). Mr. Graney will commence his purpose on 14th Oct and will be centered in Boston, MA, US. He will realize success Dominique Vanfleteren who, according to program, is leaving Oxurion to go after other passions.
Mr. Graney will be responsible for the extension and execution of the money method to aid Oxurion’s ambitious world-wide growth options, which include the vital US current market.
Tom has around 25 years’ practical experience in senior finance, method and operational roles like cash elevating, accounting, and audit. He most just lately served as CFO at Technology Bio (NASDAQ: GBIO), a non-viral gene remedy corporation primarily based in Cambridge, MA, wherever he led all of the company’s economic functions.
Prior to becoming a member of Generation Bio, Tom was Senior Vice President (SVP) and CFO at Vertex Pharmaceuticals (NASDAQ: VRTX), one particular of the world’s most extremely valued biotech firms, with a multi-billion-greenback turnover. At Vertex Tom was accountable for monetary tactic and functions together with finance, accounting, and inside audit functions.
Prior to Vertex, he was the CFO and SVP of Finance and Company Technique at Ironwood Pharmaceuticals (NASDAQ: IRWD), a GI-centered health care organization. Right before joining Ironwood, Tom expended 20 years with Johnson & Johnson, serving in numerous roles in the US and abroad, such as being Worldwide VP of Finance and CFO of Ethicon, a significant health-related device corporation, and VP and CFO of Janssen Prescribed drugs NA, a significant pharmaceutical company in North The united states.
Tom is at the moment on the board of AC Immune SA (NASDAQ: ACIU), a clinical stage Swiss biopharmaceutical business targeted on neurodegenerative illnesses.
Tom retains a Bachelor of Science degree in accounting from the University of Delaware and a Grasp of Organization Administration in advertising, finance, and intercontinental enterprise from the Leonard N. Stern Faculty of Business at New York College. Tom is also a CFA charterholder.
“We are delighted to welcome Tom to Oxurion. I am certain that Tom’s substantial financial management and US funds marketplaces experience will empower him to enjoy a crucial position in the thriving execution of our plans to produce the sector top franchise for the cure of DME, currently a $4.5 billion yearly marketplace option. With both equally Tom and Grace, our a short while ago appointed CMO, remaining primarily based in the US, we are starting up to establish the transatlantic firm we want to supply on our global ambition.
On behalf of the Board I would like to choose this possibility to thank Dominique for his contribution to Oxurion more than the past 5 a long time and for agreeing to aid us to assure a sleek transition. I would like to want him each and every success in his potential job.” reported Dr Patrik De Haes, CEO of Oxurion.
Tom Graney, the recently appointed CFO of Oxurion, extra: “I am fired up to have the option to do the job with Patrik and the staff at Oxurion. With THR-149 and THR-687, I believe Oxurion has two extremely differentiated new drug candidates that have the potential to address the wants of virtually all sufferers with DME, a critical sight threatening affliction. I am hunting ahead to using my experience to ensure Oxurion has ongoing entry to the monetary resources essential to realize its bold corporate targets.”
Oxurion Digital R&D Trader Day to consider put on Thursday 15th October 2020 at 5.30 p.m. CET/ 11.30 a.m. ET
You should seek the advice of Oxurion’s web-site for registration and connect with particulars, or follow this connection:
For even further data remember to contact:
Dr Patrik De Haes
Tel: +32 16 75 13 10
|Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi/ Frazer Corridor
Tel: +44 20 7638 9571
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing up coming technology normal of care ophthalmic therapies, which are made to far better preserve vision in patients with diabetic macular edema (DME), the foremost lead to of eyesight loss in diabetic individuals around the globe.
Oxurion is creating a foremost worldwide franchise in the treatment of DME, centered on the successful improvement of its two novel therapeutics:
·THR-149, a plasma kallikrein inhibitor currently being made as a opportunity new common of treatment for DME clients who answer sub-optimally to anti-VEGF remedy.
THR-149 has revealed beneficial topline Phase 1 outcomes for the therapy of DME. The Business is now conducting a Period 2 clinical trial analyzing THR-149 with DME-clients who earlier responded sub-optimally to anti-VEGF therapy.
THR-149 was developed in conjunction with Bicycle Therapeutics PLC (NASDAQ: BCYC).
·THR-687, is a pan-RGD integrin inhibitor, that is initially staying produced as a potential new common of treatment for all DME people.
Constructive topline results in a Phase 1 medical review examining THR-687 as a cure for DME have been declared in January 2020. THR-687 is expected to enter a Stage 2 clinical demo by mid-2021.
THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-certified from Galapagos NV (Euronext & NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and is outlined on the Euronext Brussels exchange less than the symbol OXUR.
Much more information is available at www.oxurion.com.
Significant information and facts about ahead-wanting statements
Specified statements in this push release may perhaps be thought of “forward-looking”. These kinds of ahead-wanting statements are primarily based on present anticipations, and, accordingly, entail and are affected by various challenges and uncertainties. The Company hence simply cannot provide any assurance that these types of forward-on the lookout statements will materialize and does not believe an obligation to update or revise any forward-looking assertion, whether as a result of new info, future situations, or any other explanation. Supplemental details concerning pitfalls and uncertainties influencing the small business and other factors that could trigger precise results to vary materially from any forward-hunting statement is contained in the Company’s Once-a-year Report. This press launch does not constitute an give or invitation for the sale or invest in of securities or belongings of Oxurion in any jurisdiction. No securities of Oxurion might be provided or sold inside of the United States devoid of registration beneath the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities legal guidelines.